In May, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG in ILTS 2023 Congress on Liver Transplantation, held in Rotterdam where he presented a Santersus study, aimed to investigate the effect of removal of NETs on reduction of ex-situ reperfusion injury in porcine DCD livers preserved with normothermic machine perfusion (NMP). The study concluded that NucleoCapture was able to effectively remove circulating nucleosomes/NETs from the perfusate during NMP, improving graft function and mitigating ERI.
In June, Andrew Aswani, MD, PhD (Santersus AG Chief Medical Officer) participated in ESPO JOINT E-ISFA World Congress, held in Berlin. Dr. Aswani had the opportunity to present Santersus study, which aimed to investigate the safety and performance of the NucleoCapture®Column for selective cfDNA/NETs apheresis in patients with sepsis. This first in human study of NucleoCapture® suggested that selective cfDNA/NETs apheresis in sepsis is feasible, safe and can improve the course and outcomes of the disease.
In September, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG in ESOT Congress, held in Athens. Dr Fungai has again presented the study demonstrating that the removal of chromatin associated molecular patterns (cAMPS) reduces ex-situ reperfusion injury in porcine DCD livers preserved with NMP. Dr. Fungai has revealed that the application of this technology during NMP of DCD and extended-criteria donor livers could reduce organ discard due to poor function ex-situ and be pivotal in organ optimization for transplantation.
In October, Andrew Aswani, MD, PhD (Santersus AG Chief Medical Officer) participated in 36th Annual Congress of European Society of Intensive Care and Medicine (ESICM), held in Milan. Dr. Aswani presented 3 different studies, completed by Santersus. First study demonstrated that the prolonged selective cfDNA/NETs apheresis with NucleoCapture® effectively removed cfDNA/NETs from the circulation and resulted in improved physiological indicators. The second blinded randomized controlled study demonstrated that selective cfDNA/NETs apheresis with NucleoCapture® safely and effectively removed cfDNA/NETs from the circulation of septic pigs, resulting in improved organ function and survival. Lastly, the study demonstrating the safety and performance of the NucleoCapture, suggesting that selective cfDNA/NETs apheresis in Sepsis is feasible and safe was also presented.